Trial
NCT02968121
Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Collaborators
H. Lundbeck A/S
Condition
Schizophrenia
Intervention
Brexpiprazole, OPDC-34712
Why stopped
Part A of study was completed per protocol. Conduct of Part B of the study (confirmatory phase) was not necessary.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-12